CASI Pharmaceuticals (CASIF) Total Liabilities (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Total Liabilities came in at $62.9 million in Q4 2025, up 21.44% YoY from $51.8 million in Q4 2024, and up 18.62% on a QoQ basis from $53.1 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Total Liabilities (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Total Liabilities data on file, last reported at $62.9 million in Q4 2025.
- Quarterly Total Liabilities rose 21.44% year-over-year to $62.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $62.9 million (up 21.44% YoY) and the FY2025 annual result came in at $62.9 million, up 21.44% from the prior year.
- Total Liabilities climbed to $62.9 million in Q4 2025, from $53.1 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $63.6 million in Q3 2024 to a low of $24031.0 in Q2 2023.
- A 5-year average of $36.4 million and a median of $46.8 million in 2023 frame the typical range for Total Liabilities.
- The widest YoY moves for Total Liabilities: up 121821.89% in 2025, down 99.89% in 2025.
- Tracing CASIF's Total Liabilities over 5 years: stood at $30.3 million in 2021, then dropped by 3.42% to $29.3 million in 2022, then soared by 74.4% to $51.1 million in 2023, then advanced by 1.41% to $51.8 million in 2024, then rose by 21.44% to $62.9 million in 2025.
- The last three Total Liabilities figures came in at $62.9 million (Q4 2025), $53.1 million (Q3 2025), and $51.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 79.33 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 62.93 Mn |
| Sep 30, 2025 | 53.05 Mn |
| Jun 30, 2025 | 51.51 Mn |
| Mar 31, 2025 | 48,891.00 |
| Dec 31, 2024 | 51.82 Mn |
| Sep 30, 2024 | 63.62 Mn |
| Jun 30, 2024 | 42,250.00 |
| Mar 31, 2024 | 42.54 Mn |
| Dec 31, 2023 | 51.10 Mn |
| Jun 30, 2023 | 24,031.00 |
| Dec 31, 2022 | 29.30 Mn |
| Dec 31, 2021 | 30.34 Mn |